ILife Discoveries, genetics and genomics company has introduced a new gene test in India. This will help oncologists get a deeper insight into tumors. The new MammaPrint & Blueprint test is able to analyse molecular subtypes of the cancer, risk of recurrence of early stage cancer, thereby enabling medical oncologists to take informed decisions on the course of treatment. For millions of breast cancer patients in India, the twin technologies are advancements that can shed new light on whether treatment is possible without undergoing the harsh chemotherapy process.
The area of DNA sequencing to predict cancer prognosis and development has gained attention in recent years. Actor and humanitarian Angelina Jolie had in 2013 generated much attention to gene tests that could identify the future risk of a woman suffering breast or ovarian cancer.
Blueprint is a molecular subtyping assay used in addition to the MammaPrint test in a target population of patients with early-stage (stage I or II) breast cancer. By identifying the breast cancer subtype, BluePrint allows determination of a patient’s potential level of responsiveness to chemotherapy more accurately as compared to IHC/FISH technologies, with better correlation to long-term clinical treatment outcomes.
MammaPrint is a 70-gene assay intended as a prognostic test for women of all ages. Through the gene test results, patients are stratified into two distinct groups–low risk (good prognosis) or high risk (poor prognosis) of distant recurrence. Unlike other tests, the patient is given definitive low risk and high r results, eliminating the uncertainty of an intermediate risk score which can affect up to 39 per cent of patients tested. These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions. High risk MammaPrint patients show a statistical benefit from adjuvant chemotherapy, with the FDA reporting a result accuracy of 98.5 per cent and classification accuracy of 97.7 per cent on repeat testing.
Subscribe to PharmaTutor News Alerts by Email >>
